Haggerty HG - Search Results

1

Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.

Buckley LA, Benson K, Davis-Bruno K, Dempster M, Finch GL, Harlow P, Haggerty HG, Hart T, Kinter L, Leighton JK, McNulty J, Roskos L, Saber H, Stauber A, Tabrizi M. Buckley LA, et al. Among authors: haggerty hg. Int J Toxicol. 2008 Jul-Aug;27(4):303-12. doi: 10.1080/10915810802367016. Int J Toxicol. 2008. PMID: 18821393

2

Role of metabolism in dimethylnitrosamine-induced immunosuppression: a review.

Haggerty HG, Holsapple MP. Haggerty HG, et al. Toxicology. 1990 Jul;63(1):1-23. doi: 10.1016/0300-483x(90)90064-n. Toxicology. 1990. PMID: 2200161 Review.

3

Characterization of the effects of direct alkylators on in vitro immune responses.

Haggerty HG, Kim BS, Holsapple MP. Haggerty HG, et al. Mutat Res. 1990 Sep;242(1):67-78. doi: 10.1016/0165-1218(90)90100-g. Mutat Res. 1990. PMID: 2392123

4

Production of DNA single-strand breaks in unstimulated splenocytes by dimethylnitrosamine.

Kim BS, Yang KH, Haggerty HG, Holsapple MP. Kim BS, et al. Among authors: haggerty hg. Mutat Res. 1989 Aug;213(2):185-93. doi: 10.1016/0027-5107(89)90150-4. Mutat Res. 1989. PMID: 2761556

5

Differential effects of coadministration of aminoacetonitrile on immunosuppression and hepatotoxicity produced by dimethylnitrosamine.

Haggerty HG, Boise LH, Jordan SD, Holsapple MP. Haggerty HG, et al. J Pharmacol Exp Ther. 1988 Nov;247(2):774-80. J Pharmacol Exp Ther. 1988. PMID: 3183971

6

Thymic Lymphomas in a 6-Month rasH2-Tg Mouse Carcinogenicity Study With the RORγt Inverse Agonist, BMS-986251.

Haggerty HG, Sathish JG, Gleason CR, Al-Haddawi M, Brodie TA, Bonnette KL, Lewis BS, Graziano MJ. Haggerty HG, et al. Toxicol Sci. 2021 Aug 30;183(1):93-104. doi: 10.1093/toxsci/kfab086. Toxicol Sci. 2021. PMID: 34240189

7

Decreased immune response in monkeys administered a human T-effector cell agonist (OX40) antibody.

Gamse JT, Freebern W, Haynes Ii R, Simutis F, Pazian M, Crona J, Haggerty HG, Graziano M, Bunch RT. Gamse JT, et al. Among authors: haggerty hg. Toxicol Appl Pharmacol. 2020 Dec 15;409:115285. doi: 10.1016/j.taap.2020.115285. Epub 2020 Oct 15. Toxicol Appl Pharmacol. 2020. PMID: 33069749 Free article.

8

Bioavailability of protein therapeutics in rats following inhalation exposure: Relevance to occupational exposure limit calculations.

Gould JC, Carvajal I, Davidson T, Graham J, Hillegass J, Julien S, Kozhich A, Wang B, Wei H, Yamniuk AP, Mathias N, Haggerty HG, Graziano M. Gould JC, et al. Among authors: haggerty hg. Regul Toxicol Pharmacol. 2018 Dec;100:35-44. doi: 10.1016/j.yrtph.2018.10.003. Epub 2018 Oct 3. Regul Toxicol Pharmacol. 2018. PMID: 30291877

9

Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies.

Herzyk DJ, Haggerty HG. Herzyk DJ, et al. Among authors: haggerty hg. AAPS J. 2018 Feb 7;20(2):28. doi: 10.1208/s12248-017-0184-3. AAPS J. 2018. PMID: 29417397 Review.

10

Immunomodulation and lymphoma in humans.

Ponce RA, Gelzleichter T, Haggerty HG, Heidel S, Holdren MS, Lebrec H, Mellon RD, Pallardy M. Ponce RA, et al. Among authors: haggerty hg. J Immunotoxicol. 2014 Jan-Mar;11(1):1-12. doi: 10.3109/1547691X.2013.798388. Epub 2013 Jun 7. J Immunotoxicol. 2014. PMID: 23746314 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters